Feasibility study – Identification of Prostate Cancer Recurrence Sites by [68Ga]Gallium-labelled Prostate Specific Membrane Antigen Binding Ligand Positron Emission Tomography/Magnetic Resonance Imaging (PSMA PET/MRI) in Men with Biochemical Recurrence Following Definitive Therapy

Queensland University of Technology0 个研究点目标入组 30 人开始时间: 2016年2月12日最近更新: 2020年1月13日

适应症

试验速览

暂无简介。

•1.Male patients with pathologically diagnosed prostate cancer
•2.Biochemical Recurrence as defined:
•a.PSA > 0.2ng/ml on at least 2 occasions post radical prostatectomy
•b.PSA 2.0ng/ml above nadir 2 years post radiotherapy
•3.History of primary treatment for prostate cancer no sooner than 3 months post-surgery and 2 years post radiotherapy
•4.No known problems with peripheral intravenous or central line access
•5.Able to provide informed signed consent

•1.Age under 18 years
•2.Administered a radioisotope within 5 physical half-lives prior to study enrolment
•3.Unable to lie flat during or unable to tolerate PET/MRI
•4.Prior history of any other malignancy within last 2 years
•5.Contraindication to PET scan or [68Ga]Gallium-labelled PSMA ligand
•6.Claustrophobia not manageable by oral sedatives i.e. Temazepam
•7.Renal impairment or haemodialysis.
•8.Contraindication to biopsy of identified lesion
•9. Contraindication to MRI such as implantable medical devices
•10. Body weight above 150kg or axial diameter larger than 60cm

发起方